Tower Research Capital (TRC)’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Tower Research Capital (TRC)’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,103	Closed	-$108K	–	5617
2015 Q1	$108K	Buy	1,103 +1,080	+4,696%	+$114K	0.01%	826
2014 Q4	$2K	Sell	23 -25	-52%	-$1.97K	﹤0.01%	3530
2014 Q3	$3K	Buy	+48	New	+$3.44K	﹤0.01%	3720
2014 Q2	–	Sell	-29	Closed	-$2K	–	5216
2014 Q1	$2K	Buy	+29	New	+$2.68K	﹤0.01%	4025
2013 Q4	–	Sell	-2,337	Closed	-$148K	–	5313
2013 Q3	$148K	Buy	2,337 +1,353	+138%	+$66.6K	0.02%	975
2013 Q2	$41K	Buy	+984	New	+$44.8K	﹤0.01%	1103

Tower Research Capital (TRC)'s GEVA Position: Q2 2015 in Review

Tower Research Capital (TRC) sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,103 shares — an estimated $108K sold.

Tower Research Capital (TRC) first reported a position in GEVA in Q2 2013 and held it in 6 quarters. The position peaked at $148K in Q3 2013. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Tower Research Capital (TRC) reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,103 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $108K.
Tower Research Capital (TRC) first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 6 quarters.
Tower Research Capital (TRC)'s SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $148K in Q3 2013.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2015, filed 30 Jul 2015.